Annual Report 2024
Department of Thoracic Oncology
Koichi Goto, Kiyotaka Yoh, Shingo Matsumoto, Yoshitaka Zenke, Hiroki Izumi, Tetsuya Sakai, Shigeki Umemura, Eri Sugiyama, Hibiki Udagawa, Yu Tanaka, Gaku Yamamoto, Yuki Kato, Tsuyoshi Hirata, Akari Misumi, Naoki Inoshima, Reina Idemitsu, Ken Ito, Taiki Kawai, (Seiji Niho, Kaname Nosaki, Yuji Shibata)
Introduction
The Department of Thoracic Oncology provides care for patients with primary lung cancer, mediastinal tumors, and pleural tumors. The department aims to provide the highest quality treatment and establish new effective therapies against lung cancer and other thoracic malignancies through innovative clinical and translational research. To provide comprehensive care for our patients, our staff members collaborate closely with thoracic surgeons, radiation oncologists, pathologists, pharmacists, clinical research coordinators, and psychiatrists who specialize in these areas. Moreover, residents and trainees from other institutions have joined the Thoracic Oncology Program.
The Team and What We Do
Our outpatient clinic, managed by staff members and senior residents, is open from Monday to Friday to examine all newly referred patients and evaluate returning patients. Returning patients also receive oral or intravenous chemotherapy in the Ambulatory Care Center. Bronchoscopy with EBUS for diagnosis is performed from Monday to Thursday afternoon. Fluoroscopic-CT-guided needle lung biopsies are carried out on Tuesday afternoons. We use approximately 50-60 beds for patient management, mainly in the 8F, 6A, 6B, and 5A wards.
Case conferences on thoracic surgery and medical oncology are scheduled on Tuesday evenings and Wednesday evenings, respectively. The staff members and residents of the division participate in a journal club on Monday and Wednesday mornings. At monthly meetings with physicians in private hospitals, the staff and residents teach reading methods for chest X-rays and CT images.
Research Activities
Our research activities are focused on three areas: 1) the development of new and effective diagnosis and treatment modalities in lung cancer; 2) collaborative studies with the Research Center for Innovative Oncology in the following areas: detection of biomarkers for the treatment of advanced lung cancer; development of new diagnostic methods of rare driver genomic alteration for lung cancer; correlation between genomic abnormalities and clinical characteristics and treatment in lung cancer; correlation between pathological features and sensitivity of treatments in lung cancer; and 3) translational research from bench to bedside or from bed-side to bench for the development of innovative treatment strategies in lung cancer.
Notably, high-spec genomic analysis technologies are being adapted for our research screening of rare driver genomic alterations in lung cancer, such as RET, ROS1, BRAF, MET, and HER2, among others. Collaborations with diagnostic companies also support their clinical development.
Clinical Trials
The Department of Thoracic Oncology is currently conducting and participating in multi-institutional clinical studies for advanced lung cancer, including the Japan Clinical Oncology Group (JCOG) trials, investigator-initiated trials, and pharmaceutical company-initiated global trials.
A genomic screening platform in Japan established by our department, LC-SCRUM-Asia, was initiated in 2013 and is now ongoing. As of March 2025, 344 Japanese institutions had participated in LC-SCRUM-Japan, and 23,786 patients had been enrolled. In the fifth stage of LC-SCRUM-Asia, initiated in June 2024, small-cell lung cancer has also been included in the screening histology, and a new screening method using multiple immunohistochemistry has been undertaken to contribute to the clinical development of antibody-drug conjugates. In addition, the Asia-Pacific international genomic screening initiative, involving Taiwan, Thailand, and Malaysia, known as LC-SCRUM-AP, was initiated in January 2023 and is currently ongoing. As of March 2025, 331 patients were already enrolled, and the project aims to promote precision medicine in Asia-Pacific countries. LC-SCRUM-Asia will support the development of novel therapeutic and diagnostic products, contributing to the establishment of precision medicine in Asian countries. Many lung cancers with rare driver oncogenes, such as RET, ROS1, BRAF, MET, HER2, NTRK, and KRAS G12C, have been identified in our screening and entered into various clinical trials of molecular-targeting agents. Based on the results of clinical trials leveraging genomic screening in LC-SCRUM-Asia, crizotinib was approved for ROS1 fusion-positive lung cancer in May 2017, dabrafenib/Trametinib was approved for BRAF V600E mutation-positive lung cancer in March 2018, entrectinib was approved for NTRK and ROS1 fusion-positive lung cancer in June 2019 and February 2020, respectively, and tepotinib and capmatinib were approved for MET ex14 skipping positive lung cancer in March 2020 and June 2020, respectively. In addition, selpercatinib was approved for RET fusion-positive lung cancer in September 2021, sotorasib was approved for KRAS G12C mutation-positive lung cancer in January 2022, and trastuzumab deruxtecan (T-DXd) was approved for HER2 mutation-positive lung cancer in August 2023. In 2024, gumarontinib was approved for MET ex14 skipping-positive lung cancer in June 2024, repotrectinib was approved for ROS1 fusion-positive lung cancer in September 2024, and amivantamab was approved for EGFR Ex20 insertion mutation-positive lung cancer in September 2024, making LC-SCRUM-Asia a significant achievement in the development of treatments for lung cancers with rare driver oncogenes.
The RT-PCR kit, which was adopted in LC-SCRUM-Asia screening for ROS1 fusion, was simultaneously approved for use in our screening data as a companion diagnostic (CDx) for ROS1-positive lung cancer in January 2017. Similarly, the next-generation sequencing (NGS) panel, Oncomine DxTT (ODxTT), was first approved as a companion diagnostic (CDx) for BRAF mutation-positive lung cancer in April 2018, marking a significant step forward in the clinical application of NGS multi-diagnostics. ODxTT eventually became an NGS multi-CDx for seven genomic alterations: EGFR/ALK/ROS1/BRAF/RET/HER2/MET, by March 2025, significantly contributing to the development of precision medicine in lung cancer. In addition, the multi-PCR panel, AmoyDx Pan Lung Cancer PCR Panel, with a short turnaround time, was approved as a multi-CDx for seven genomic alterations: EGFR/ALK/ROS1/BRAF/MET/RET/KRAS, by March 2025. As a result, we can obtain the results of multi-genomic analysis within a week and initiate precision medicine for lung cancer from first-line treatment in clinical practice. Through genomic screening and the establishment of a clinical-genomic database, LC-SCRUM-Asia plays a crucial role in developing precision medicine for lung cancer in Japan and other Asian countries.
In addition to targeted genomic screening to identify novel oncogenic driver genes, we initiated whole-transcriptome sequencing (WTS) of NSCLC samples negative for known oncogenic drivers in the LC-SCRUM-Asia cohort from October 2020. In the WTS, we identified an in-frame fusion transcript of CLIP1 on chromosome 12q24 and LTK on chromosome 15q15 in one patient. The CLIP1-LTK fusion was present in 0.4% of NSCLCs and was mutually exclusive to other known oncogenic drivers. We showed that the kinase activity of the CLIP1-LTK fusion protein was constitutively activated and had transformation potential. In vitro and in vivo analysis showed that the treatment with lorlatinib, an ALK inhibitor, inhibited CLIP1-LTK kinase activity, suppressed proliferation, and induced apoptosis. One patient with NSCLC harboring the CLIP1-LTK fusion showed an excellent clinical response to lorlatinib. This was the first description of LTK alterations with oncogenic activity in cancers, published in Nature in November 2021. Moreover, we initiated an investigator-initiated trial of Lorlatinib for CLIP1-LTK fusion-positive lung cancer in February 2023, which is ongoing.
We also initiated an additional genomic screening project for pre-treated patients to identify resistant genomic alterations after treatment with molecular targeting agents (LC-SCRUM-TRY) in September 2020. A total of 1,868 pre-treated patients were already enrolled in LC-SCRUM-TRY as of March 2025. We challenge the establishment of precision medicine by leveraging genomic screening of LC-SCRUM-TRY to overcome resistance mechanisms to previous treatments. Additionally, we initiated a new genomic screening project (LC-SCRUM-Advantage/MRD) for patients with lung cancers, primarily stage I-III, who underwent surgical resection in August 2022. This project aims to establish precision medicine in perioperative treatment and to clarify the clinical significance of microresidual disease (MRD) in blood samples. A total of 966 patients were already enrolled in LC-SCRUM-Advantage/MRD as of March 2025.
To select the optimal treatment for individual patients with advanced lung cancer, we currently need to identify genomic alterations by genomic tests and perform PD-L1 immunohistochemical staining using tissue samples in clinical practice. Since we aim to obtain as many high-quality tissue samples as possible by bronchoscopy for biomarker analyses, we conduct a feasibility study of the cutting-edge trans-bronchial biopsy technique to evaluate its utility.
Education
Residents, cancer specialists in training, and staff are paired to provide outpatient/inpatient medical care and perform examinations. The aim is to develop clinicians who can provide comprehensive medical care for patients with thoracic malignant tumors, from diagnosis to treatment, including palliative care, by closely supporting patients with advanced lung cancer for whom a complete cure is difficult. Moreover, our department continually strives to train specialists with outstanding minds and powerful mental and physical capabilities to handle patients' distress effectively. Residents must rotate through the Department of Pathology during their training period and have opportunities to engage with basic research conducted within this department. Furthermore, we actively support the preparation of manuscripts on basic and clinical research, aiming to develop clinicians capable of conducting clinical and translational research. In addition, one thoracic oncologist is affiliated with the Joint Graduate Program at Juntendo University, and a specialized researcher has been studying at MD Anderson Cancer Center in the United States since April 2023. Additionally, one staff member is seconded to the PMDA, and another to a pharmaceutical company. We strive to help staff advance their careers by providing them with as much experience as possible in basic research, treatment development, and interactions with regulatory authorities.
A joint case conference with the Department of Thoracic Surgery is held every Tuesday. A joint case conference with the Department of Radiation Oncology is held every Wednesday to determine treatment policies and protocols. A research conference is held biweekly to discuss the progress and schedule of research with all members. A journal club with the Department of Thoracic Oncology is held every Monday, a journal club with the Department of Thoracic Surgery is held every Wednesday, a joint conference with the Departments of Thoracic Surgery and Pathology is held every Friday, and a chest X-ray reading meeting for local clinicians is held on the second Tuesday of each month. A chest X-ray reading meeting with the Katsushika Medical Association is held on the fourth Tuesday of each month.
Future Prospects
Drug therapy for lung cancer has undergone a significant shift toward precision medicine, in which therapeutic drugs are selected based on biomarkers specific to individual patients. In addition, immune checkpoint inhibitors have significantly contributed to improving treatment outcomes in lung cancer, as highly effective drugs with a distinct mechanism of action from conventional treatments. Dramatic advances in these new therapies have significantly altered the treatment landscape for advanced lung cancer over the last few years, and treatment outcomes have also shown substantial improvement. In our department, we plan to continue conducting various research to establish precision medicine for lung cancer based on biomarkers. Additionally, Asian countries such as Taiwan, Thailand, Malaysia, and Vietnam are participating in LC-SCRUM-Asia, and we aim to establish a large-scale international genomic screening platform across the Asia-Pacific region. By leveraging this screening platform, treatment development for advanced lung cancer, which has garnered significant attention worldwide, will be conducted, and the results will be made available globally. Moreover, we will continue to promote translational research, conduct innovative and advanced clinical trials that can link the results to clinical development, and pursue research to overcome advanced lung cancer.
List of papers published in 2024
Journal
1. Qi Z, Ha T, Feng W, Karnoub M, Pereira K, Shiga R, Smit EF, Goto Y, De Langen AJ, Goto K, Velasco Roth AM, Khambata-Ford S. Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies. Archives of pathology & laboratory medicine, 149:542-549, 2025
2. Umemura S, Udagawa H, Ikeda T, Murakami H, Daga H, Toyozawa R, Kozuki T, Sakakibara-Konishi J, Ohe Y, Morise M, Kato T, Shingyoji M, Hara S, Furuya N, Teranishi S, Takata S, Miyamoto S, Nakachi I, Wakabayashi M, Nomura S, Sato A, Ishii G, Tsuchihara K, Sugiyama E, Kirita K, Sakai T, Shibata Y, Izumi H, Nosaki K, Zenke Y, Matsumoto S, Yoh K, Niho S, Goto K. Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib. Journal of thoracic oncology, 20:177-193, 2025
3. Sekino Y, Hishida T, Yoshioka H, Wakabayashi M, Mitome N, Shiono S, Kenmotsu H, Nosaki K, Aokage K, Horinouchi H, Fukuda H, Ohe Y, Watanabe SI. Protocol summary of a randomized phase III study: comparing systemic therapy with and without debulking surgery (primary tumour resection) for clinical stage IVA (cT1-2bN0-1M1a) non-small cell lung cancer with radiologically undetermined pleural dissemination JCOG2103 (DEBULK-LUNG). Japanese journal of clinical oncology, 55:176-182, 2025
4. Oi H, Taki T, Kuroe T, Sakamoto N, Sakashita S, Kojima M, Sugiyama E, Umemura S, Sakai T, Izumi H, Zenke Y, Matsumoto S, Yoh K, Ishii M, Tsuboi M, Goto K, Ishii G. NETosis in pulmonary pleomorphic carcinoma. Cancer science, 116:524-532, 2025
5. Blechter B, Hsiung CA, Wang X, Zhang H, Seow WJ, Shi J, Chatterjee N, Kim HN, Wong MP, Hong YC, Wong JYY, Dai J, Hosgood HD, Wang Z, Chang IS, Choi J, Wang J, Song M, Hu W, Zheng W, Kim JH, Zhou B, Albanes D, Shin MH, Chung LP, An SJ, Zheng H, Yatabe Y, Zhang XC, Kim YT, Shu XO, Kim YC, Vermeulen RCH, Bassig BA, Chang J, Man Ho JC, Ji BT, Kubo M, Daigo Y, Momozawa Y, Kamatani Y, Honda T, Kunitoh H, Watanabe SI, Miyagi Y, Nakayama H, Matsumoto S, Tsuboi M, Goto K, Yin Z, Takahashi A, Goto A, Minamiya Y, Shimizu K, Tanaka K, Wu T, Wei F, Su J, Kim YH, Oh IJ, Fun Lee VH, Su WC, Chen YM, Chang GC, Chen KY, Huang MS, Lin HC, Seow A, Park JY, Kweon SS, Chen CJ, Gao YT, Wu C, Qian B, Lu D, Liu J, Jeon HS, Hsiao CF, Sung JS, Tsai YH, Jung YJ, Guo H, Hu Z, Chen TY, Burdett L, Yeager M, Hutchinson A, Berndt SI, Wu W, Wang J, Choi JE, Park KH, Sung SW, Liu L, Kang CH, Chen CH, Xu J, Guan P, Tan W, Wang CL, Loon Sihoe AD, Chen Y, Choi YY, Kim JS, Yoon HI, Cai Q, Park IK, Xu P, He Q, Chen CY, Wu J, Lim WY, Chen KC, Chan JKC, Li J, Chen H, Yu CJ, Jin L, Fraumeni JF Jr, Liu J, Landi MT, Yamaji T, Yang Y, Hicks B, Wyatt K, Li SA, Ma H, Song B, Wang Z, Cheng S, Li X, Ren Y, Iwasaki M, Zhu J, Jiang G, Fei K, Wu G, Chien LH, Tsai FY, Yu J, Stevens VL, Yang PC, Lin D, Chen K, Wu YL, Matsuo K, Rothman N, Shiraishi K, Shen H, Chanock SJ, Kohno T, Lan Q. Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR Mutation Status: A Brief Report. Journal of thoracic oncology, 20:521-530, 2025
6. Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Nishino K, Yoh K, Shih JY, Chik JYK, Moro-Sibilot D, Puri T, Chacko Varughese S, Frimodt-Moller B, Visseren-Grul C, Reck M. RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC. Journal of thoracic oncology, 20:487-499, 2025
7. Sonehara K, Tateishi K, Yoh K, Usui K, Hosomi Y, Kishi K, Naka G, Watanabe K, Tamano S, Uemura K, Kunitoh H. Real-World Study of EGFR-TKI Rechallenge With Another TKI After First-Line Osimertinib Discontinuation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study. Thoracic cancer, 16:e15507, 2025
8. Awano N, Yoh K, Usui K, Hosomi Y, Kishi K, Naka G, Watanabe K, Tamano S, Uemura K, Kunitoh H. Outcome of osimertinib-treated patients with epidermal growth factor receptor mutation-positive nonsmall cell lung cancer requiring dose reduction: a secondary analysis of the Reiwa study. Japanese journal of clinical oncology, 55:261-268, 2025
9. Kobayashi T, Watanabe K, Hosomi Y, Yoh K, Usui K, Kishi K, Naka G, Tamano S, Uemura K, Kunitoh H. Clinical outcomes of patients with EGFR-mutated NSCLC developing interstitial lung disease during first-line osimertinib therapy: a sub-analysis of the Reiwa study. Japanese journal of clinical oncology, 55:275-282, 2025
10. Hirata T, Watanabe K, Hosomi Y, Yoh K, Usui K, Kishi K, Naka G, Tamano S, Uemura K, Kunitoh H. Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer. Japanese journal of clinical oncology, 55:269-274, 2025
11. Ito Y, Zenke Y, Sakai T, Shibata Y, Izumi H, Nosaki K, Umemura S, Matsumoto S, Yoh K, Nakamura M, Hojo H, Izumo T, Goto K. A simplified scoring system for predicting treatment response in limited-stage small-cell lung cancer (EAST score). Future oncology (London, England), 21:473-481, 2025
12. Takeda M, Ota M, Iwama E, Sugawara S, Shukuya T, Umemura S, Tanaka H, Oki M, Takahama T, Masuda T, Nogami N, Shimokawa M. A Phase II, Open Label, Single-Arm Study on the Efficacy of Cabozantinib in Patients With Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring MET Exon 14 Alterations who Developed Acquired Resistance to Tepotinib or Capmatinib (CAPTURE Trial). Clinical lung cancer, 26:e232-e235, 2025
13. Besse B, Goto K, Wang Y, Lee SH, Marmarelis ME, Ohe Y, Bernabe Caro R, Kim DW, Lee JS, Cousin S, Ichihara E, Li Y, Paz-Ares L, Ono A, Sanborn RE, Watanabe N, de Miguel MJ, Helissey C, Shu CA, Spira AI, Tomasini P, Yang JC, Zhang Y, Felip E, Griesinger F, Waqar SN, Calles A, Neal JW, Baik CS, Jänne PA, Shreeve SM, Curtin JC, Patel B, Gormley M, Lyu X, Chen J, Chu PL, Mahoney J, Trani L, Bauml JM, Thayu M, Knoblauch RE, Cho BC. Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A. Journal of thoracic oncology, 20:651-664, 2025
14. Sands J, Ahn MJ, Lisberg A, Cho BC, Blumenschein G Jr, Shum E, Pons Tostivint E, Goto Y, Yoh K, Heist R, Shimizu J, Lee JS, Baas P, Planchard D, Pérol M, Felip E, Su WC, Zebger-Gong H, Lan L, Liu C, Howarth P, Chiaverelli R, Paz-Ares L. Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study. Journal of clinical oncology, 43:1254-1265, 2025
15. Spira A, Cho BC, Felip E, Garon EB, Goto K, Johnson M, Leighl N, Passaro A, Planchard D, Popat S, Yang JC, Lu X, Jiang Y, Huang J, Lam M, Kowanetz M, Wang S, Le J, Hsu JY, Zhou CC. FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004). Lung cancer (Amsterdam, Netherlands), 199:108066, 2025
16. Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Bolotin E, Blot V, Goldman J. Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. Annals of oncology, 36:583-591, 2025
17. Sands JM, Champiat S, Hummel HD, Paulson KG, Borghaei H, Alvarez JB, Carbone DP, Carlisle JW, Choudhury NJ, Clarke JM, Gadgeel SM, Izumi H, Navarro A, Lau SCM, Lammers PE, Huang S, Hamidi A, Mukherjee S, Owonikoko TK. Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer. Cancer, 131:e35738, 2025
18. Qi Z, Tokuhiro S, Odegaard JI, Wienke S, Karnoub M, Feng W, Shiga R, Smit EF, Goto Y, De Langen AJ, Goto K, Pereira K, Khambata-Ford S. Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non-Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02. The Journal of molecular diagnostics : JMD, 27:119-129, 2025
19. Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O'Reilly EM, Ou SI, Rodon J, Rha SY, Nishino K, Duruisseaux M, Park JO, Neuzillet C, Liu SV, Weinberg BA, Cleary JM, Calvo E, Umemoto K, Nagasaka M, Springfeld C, Bekaii-Saab T, O'Kane GM, Opdam F, Reiss KA, Joe AK, Wasserman E, Stalbovskaya V, Ford J, Adeyemi S, Jain L, Jauhari S, Drilon A. Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. The New England journal of medicine, 392:566-576, 2025
20. Gautschi O, Park K, Solomon BJ, Tomasini P, Loong HH, De Braud F, Goto K, Peterson P, Barker S, Liming K, Oxnard GR, Frimodt-Moller B, Drilon A. Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial. Journal of clinical oncology, 43:1758-1764, 2025
21. Uehara Y, Izumi H, Taki T, Sakai T, Udagawa H, Sugiyama E, Umemura S, Zenke Y, Matsumoto S, Yoh K, Kubota S, Aokage K, Sakamoto N, Sakashita S, Kojima M, Nagamine M, Hosomi Y, Tsuboi M, Goto K, Ishii G. Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma. JTO clinical and research reports, 6:100779, 2025
22. Heymach JV, Opdam F, Barve M, Tu HY, Wu YL, Berz D, Schröter L, Botilde Y, Sadrolhefazi B, Serra J, Yoh K, Yamamoto N. HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study. Journal of clinical oncology, 43:1337-1347, 2025
23. Nogami N, Umemura S, Kozuki T, Zenke Y, Ohtani J, Ishii M, Han S, Noguchi K, Horinouchi H. A phase 1 study of pembrolizumab plus ipilimumab as first-line treatment in Japanese patients with advanced non-small-cell lung cancer. Respiratory investigation, 63:296-302, 2025
24. Shukuya T, Asao T, Goto Y, Mimori T, Takayama K, Kaira K, Tanaka H, Ko R, Amano Y, Tachihara M, Suzuki T, Tanizaki J, Sugawara S, Zenke Y, Shirai Y, Hayashi T, Mori K, Takahashi K. Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial. The Lancet. Oncology, 26:331-342, 2025
25. Uehara Y, Izumi H, Kobayashi IS, Matsumoto S, Hosomi Y, Okuno T, Sugisaka J, Takase N, Taima K, Sasaki S, Teranishi S, Miyamoto S, Mori M, Nakashima C, Asano S, Oi H, Sakai T, Shibata Y, Udagawa H, Sugiyama E, Nosaki K, Umemura S, Zenke Y, Yoh K, Ikeda S, Costa DB, Kobayashi SS, Goto K. Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry). Lung cancer (Amsterdam, Netherlands), 202:108479, 2025
26. Kanda S, Niho S, Kurata T, Nomura S, Kawashima Y, Iwama E, Yokoyama T, Watanabe Y, Tanaka H, Fujiwara Y, Zenke Y, Azuma K, Taniguchi H, Toyozawa R, Hosomi Y, Murakami H, Hara S, Bessho A, Yamamoto N, Ohe Y. Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-doublet Chemotherapy for Non-small Cell Lung Cancer Harboring EGFR Mutation. Clinical cancer research, 31:2317-2326, 2025
27. Morise M, Kato T, Matsumoto S, Inoue T, Sakamoto T, Tokito T, Atagi S, Kozuki T, Takeoka H, Chikamori K, Shinagawa N, Tanaka H, Horii E, Adrian S, Bruns R, Johne A, Paik PK, Sakai H. Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study. Cancer science, 115:1296-1305, 2024
28. Tsukita Y, Taguri M, Goto Y, Hosomi Y, Mizutani T, Watanabe K, Yoh K, Takahashi S, Kubota K, Kunitoh H. Multi-institutional study of osimertinib dose-optimization in non-small cell lung cancer patients with EGFR activating mutation aged 70 years or older ('MONEY' trial). Japanese journal of clinical oncology, 54:730-734, 2024
29. Yamamoto N, Satouchi M, Doi T, Fujiwara Y, Yanagitani N, Kawa Y, Yoh K, Leopold L, Munteanu M, Sawada T, Han S, Noguchi K, Nishio M. KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer. Investigational new drugs, 42:261-271, 2024
30. Mori S, Izumi H, Araki M, Liu J, Tanaka Y, Kagawa Y, Sagae Y, Ma B, Isaka Y, Sasakura Y, Kumagai S, Sakae Y, Tanaka K, Shibata Y, Udagawa H, Matsumoto S, Yoh K, Okuno Y, Goto K, Kobayashi SS. LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion. Communications biology, 7:412, 2024
31. Mimura C, Takamiya R, Fujimoto S, Fukui T, Yatani A, Yamada J, Takayasu M, Takata N, Sato H, Fukuda K, Furukawa K, Hazama D, Katsurada N, Yamamoto M, Matsumoto S, Goto K, Tachihara M. Utility of bronchoscopically obtained frozen cytology pellets for next-generation sequencing. BMC cancer, 24:489, 2024
32. Kuboki Y, Koyama T, Matsubara N, Naito Y, Kondo S, Harano K, Yonemori K, Yoh K, Gu Y, Mita T, Chen X, Ueda E, Yamamoto N, Doi T, Shimizu T. PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study. Cancer medicine, 13:e6980, 2024
33. Okahisa M, Udagawa H, Matsumoto S, Kato T, Yokouchi H, Furuya N, Kanemaru R, Toyozawa R, Nishiyama A, Ohashi K, Miyamoto S, Nishino K, Nakamura A, Iwama E, Niho S, Oi H, Sakai T, Shibata Y, Izumi H, Sugiyama E, Nosaki K, Umemura S, Zenke Y, Yoh K, Kah Mun Low G, Zhuo J, Goto K. Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia. Lung cancer (Amsterdam, Netherlands), 191:107798, 2024
34. Nosaki K, Yoh K, Toyozawa R, Horinouchi H, Morise M, Ohashi K, Murakami H, Satouchi M, Sakakibara-Konishi J, Yano S, Okumura F, Matsumoto S, Shimokawa M, Seto T, Goto K. Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study. International journal of clinical oncology, 29:1142-1151, 2024
35. Pérol M, Solomon BJ, Goto K, Park K, Nadal E, Bria E, Martin C, Bar J, Williams JN, Puri T, Li J, Uh MK, Lin BK, Zhou C. CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer. Journal of clinical oncology, 42:2500-2505, 2024
36. Hasegawa T, Okuyama T, Uemura T, Matsuda Y, Otani H, Shimizu J, Horio Y, Watanabe N, Yamaguchi T, Fukuda S, Oguri T, Maeno K, Inagaki Y, Nosaki K, Fukumitsu K, Akechi T. Unrealistic expectations and disclosure of incurability in patients with non-small cell lung cancer. Supportive care in cancer, 32:421, 2024
37. Takeda M, Shimokawa M, Nakamura A, Nosaki K, Watanabe Y, Kato T, Hayakawa D, Tanaka H, Takahashi T, Oki M, Tachihara M, Fujimoto D, Hayashi H, Yamaguchi K, Yamamoto S, Iwama E, Azuma K, Hasegawa K, Yamamoto N, Nakagawa K. Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy" [Lung Cancer 177 (2023) 44-50]. Lung cancer (Amsterdam, Netherlands), 193:107852, 2024
38. Kodama H, Murakami H, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ko R, Ono A, Kenmotsu H, Naito T, Matsumoto S, Goto K, Shimizu T, Gon Y, Takahashi T. Suitability of frozen cell pellets from cytology specimens for the Amoy 9-in-1 assay in patients with non-small cell lung cancer. Thoracic cancer, 15:1665-1672, 2024
39. Kubo K, Igaue S, Utsunomiya D, Kubo Y, Kanematsu K, Kurita D, Ishiyama K, Oguma J, Goto K, Daiko H. Preoperative neutrophil-to-lymphocyte ratio predicts recurrence of esophageal squamous cell carcinoma after neoadjuvant triplet chemotherapy. General thoracic and cardiovascular surgery, 72:802-809, 2024
40. Goto K. Rain Leaks Under the Trusted Tree. Journal of thoracic oncology, 19:963-965, 2024
41. Niho S, Goto Y, Toyozawa R, Daga H, Ohashi K, Takahashi T, Tanaka H, Sakakibara-Konishi J, Hattori Y, Morise M, Kodani M, Ikeda T, Izumi H, Matsumoto S, Yoh K, Nomura S, Goto K. Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study. ESMO open, 9:103642, 2024
42. Barlesi F, Cho BC, Goldberg SB, Yoh K, Zimmer Gelatti AC, Mann H, Gopinathan A, Bielecka ZF, Newton M, Aggarwal C. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer. Future oncology (London, England), 20:2137-2147, 2024
43. Himeji D, Shiiba R, Tanaka GI, Takano A, Kamiike R, Kushima N, Matsumoto S, Goto K, Maekawa K, Marutsuka K. Usefulness of endoscopic ultrasound with bronchoscope-guided fine-needle aspiration for next-generation sequencing in patients with non-small cell lung cancer: A comparison with other bronchoscopic techniques. Respiratory investigation, 62:879-883, 2024
44. Izumi M, Fujii M, Kobayashi IS, Ho V, Kashima Y, Udagawa H, Costa DB, Kobayashi SS. Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer. Cell death & disease, 15:580, 2024
45. Nishio M, Watanabe S, Udagawa H, Aragane N, Nakagawa Y, Kobayashi Y, Saito H. Integrated analysis of older adults and patients with renal dysfunction in the IMpower130 and IMpower132 randomized controlled trials for advanced non-squamous non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 196:107859, 2024
46. Watanabe K, Sasaki K, Machida R, Shimizu J, Yamane Y, Tamiya M, Saito S, Takada Y, Yoh K, Yoshioka H, Murakami H, Kitazono S, Goto Y, Horinouchi H, Ohe Y. High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group). Japanese journal of clinical oncology, 54:1084-1092, 2024
47. Shiraishi Y, Nomura S, Sugawara S, Horinouchi H, Yoneshima Y, Hayashi H, Azuma K, Hara S, Niho S, Morita R, Yamaguchi M, Yokoyama T, Yoh K, Kurata T, Okamoto H, Okamoto M, Kijima T, Kasahara K, Fujiwara Y, Murakami S, Kanda S, Akamatsu H, Takemoto S, Kaneda H, Kozuki T, Ando M, Sekino Y, Fukuda H, Ohe Y, Okamoto I. Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial. The Lancet. Respiratory medicine, 12:877-887, 2024
48. Yoh K, Azuma K, Hayashi H, Nishio M, Chikamori K, Ichihara E, Watanabe Y, Asato T, Kitagawa T, Fram RJ, Ohe Y. A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations. International journal of clinical oncology, 29:1461-1474, 2024
49. Dowlati A, Hummel HD, Champiat S, Olmedo ME, Boyer M, He K, Steeghs N, Izumi H, Johnson ML, Yoshida T, Bouchaab H, Borghaei H, Felip E, Jost PJ, Gadgeel S, Chen X, Yu Y, Martinez P, Parkes A, Paz-Ares L. Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update. Journal of clinical oncology, 42:3392-3399, 2024
50. Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A, Bernabe R, Buchmeier EL, Chang JW, Shiraishi Y, Sezgin Goksu S, Badzio A, Shi A, Daniel DB, Hoa NTT, Zemanova M, Mann H, Gowda H, Jiang H, Senan S. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. The New England journal of medicine, 391:1313-1327, 2024
51. Morgensztern D, Ready N, Johnson ML, Dowlati A, Choudhury N, Carbone DP, Schaefer E, Arnold SM, Puri S, Piotrowska Z, Hegde A, Chiang AC, Iams W, Tolcher A, Nosaki K, Kozuki T, Li T, Santana-Davila R, Akamatsu H, Murakami H, Yokouchi H, Wang S, Zha J, Li R, Robinson RR, Hingorani P, Jeng EE, Furqan M. A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer. Clinical cancer research, 30:5042-5052, 2024
52. Watanabe K, Hosomi Y, Naoki K, Nakahara Y, Tsukita Y, Matsumoto H, Yoh K, Fujisaka Y, Takahashi S, Takata S, Usui K, Kishi K, Naka G, Tamano S, Uemura K, Kunitoh H. The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study). JTO clinical and research reports, 5:100720, 2024
53. Kato Y, Udagawa H, Matsumoto S, Izumi H, Ohe Y, Kato T, Nishino K, Miyamoto S, Kawana S, Chikamori K, Shingyoji M, Sato Y, Takada Y, Toyozawa R, Azuma K, Tanaka Y, Sakai T, Shibata Y, Sugiyama E, Nosaki K, Zenke Y, Umemura S, Yoh K, Seike M, Goto K. Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia. Lung cancer (Amsterdam, Netherlands), 197:107992, 2024
54. Lim SM, Schalm SS, Lee EJ, Park S, Conti C, Millet YA, Woessner R, Zhang Z, Tavera-Mendoza LE, Stevison F, Albayya F, Dineen TA, Hsieh J, Oh SY, Zalutskaya A, Rotow J, Goto K, Lee DH, Yun MR, Cho BC. BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer. Therapeutic advances in medical oncology, 16:17588359241280689, 2024
55. Aokage K, Koyama S, Kumagai S, Nomura K, Shimada Y, Yoh K, Wakabayashi M, Fukutani M, Furuya H, Miyoshi T, Tane K, Samejima J, Taki T, Hayashi T, Matsubayashi J, Ishii G, Nishikawa H, Ikeda N, Tsuboi M. Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY). Clinical cancer research, 30:5584-5592, 2024
56. Wu X, Adame-Garcia SR, Koshizuka K, Vo PTT, Hoang TS, Sato K, Izumi H, Goto Y, Allevato MM, Wood KC, Lippman SM, Gutkind JS. Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism. Cancer prevention research (Philadelphia, Pa.), 17:571-583, 2024
57. Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Alvarez JB, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, Martinez P, Anderson ES, Paz-Ares L. Plain language summary: tarlatamab for patients with previously treated small cell lung cancer. Future oncology (London, England), 20:3355-3364, 2024
58. Matsumoto Y, Umemura S, Okizaki A, Fujisawa D, Yamaguchi T, Oyamada S, Miyaji T, Mashiko T, Kobayashi N, Satomi E, Kiuchi D, Morita T, Uchitomi Y, Goto K, Ohe Y. Nurse-Led Screening-Triggered Early Specialized Palliative Care Program for Patients With Advanced Lung Cancer: A Multicenter Randomized Controlled Trial. Cancer medicine, 13:e70325, 2024
59. Karayama M, Suda T, Yoh K, Usui K, Hosomi Y, Kishi K, Naka G, Watanabe K, Tamano S, Uemura K, Kunitoh H. Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study. Lung cancer (Amsterdam, Netherlands), 198:108037, 2024